Cargando…

Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency

We report a case of a 64-year-old man who, 44 days after starting treatment with prasugrel, presented with severe thrombocytopenia, anaemia, renal failure, and severe ADAMTS13 activity deficiency, along with a high titer of autoantibodies to this protease. LEARNING POINTS: Drug-induced TTP is a rare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez, Yanet Parodis, Gonzalez, Nery Sablon, Villalba, Noel Lorenzo, Galvan, Rafael Camacho, Perez, Jose Carlos Rodriguez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SMC Media Srl 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346962/ https://www.ncbi.nlm.nih.gov/pubmed/30755885 http://dx.doi.org/10.12890/2016_000446

Ejemplares similares

Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017)

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
por: Thomas, Mari R., et al.
Publicado: (2015)

Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura
por: Edgar, Contessa E., et al.
Publicado: (2015)

Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan
por: Matsumoto, Masanori, et al.
Publicado: (2012)

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Bonnez, Quintijn, et al.
Publicado: (2023)

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
por: Graça, Nuno A. G., et al.
Publicado: (2019)

ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
por: Joly, Bérangère S., et al.
Publicado: (2022)

Congenital Thrombotic Thrombocytopenic Purpura With a Novel ADAMTS13 Gene Mutation
por: Rashid, Anila, et al.
Publicado: (2020)

Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura
por: Deforche, Louis, et al.
Publicado: (2016)

ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura
por: Manea, Minola, et al.
Publicado: (2006)

Relapsing thrombotic thrombocytopenic purpura with low ADAMTS13 antigen levels: An indication for splenectomy?
por: Lombardi, Anna Maria, et al.
Publicado: (2019)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
por: Sakai, Kazuya, et al.
Publicado: (2022)

Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?
por: Lancellotti, Stefano, et al.
Publicado: (2023)

Histone-induced thrombotic thrombocytopenic purpura in adamts13(−/−) zebrafish depends on von Willebrand factor
por: Zheng, Liang, et al.
Publicado: (2020)

Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay
por: Beranger, Nicolas, et al.
Publicado: (2020)

Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
por: Sinkovits, György, et al.
Publicado: (2018)

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura
por: Kangro, Kadri, et al.
Publicado: (2020)

Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach
por: Patrick, Tiffany, et al.
Publicado: (2012)

Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child
por: Borgi, A., et al.
Publicado: (2013)

Positive Response and Increase in ADAMTS13 with Scheduled Rituximab in a Patient with Relapsing Thrombotic Thrombocytopenic Purpura
por: Amer, Bahaa, et al.
Publicado: (2019)

Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Vendramin, Chiara, et al.
Publicado: (2018)

An ADAMTS13 mutation that causes hereditary thrombotic thrombocytopenic purpura: a case report and literature review
por: Li, Pengzhu, et al.
Publicado: (2021)

De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura
por: Alharbi, Ibrahim, et al.
Publicado: (2021)

Economic impact of a rapid, on‐demand ADAMTS‐13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura
por: White, Alicia, et al.
Publicado: (2022)

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications
por: Dainese, Cristina, et al.
Publicado: (2022)

Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Tozinameran: Acquired thrombotic thrombocytopenic purpura: case report
Publicado: (2022)

Hereditary Thrombotic Thrombocytopenic Purpura in a Chinese Boy With a Novel Compound Heterozygous Mutation of the ADAMTS13 Gene
por: Dai, Yi-ling, et al.
Publicado: (2020)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia
por: Pandey, Ramesh Kumar, et al.
Publicado: (2017)

Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Tozinameran: Acquired thrombotic thrombocytopenic purpura: 4 case reports
Publicado: (2021)

AZD-1222: Acquired thrombotic thrombocytopenic purpura: case report
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

Dengue and Thrombotic Thrombocytopenic Purpura
por: Wiwanitkit, Viroj
Publicado: (2017)

Vaccination and Thrombotic Thrombocytopenic Purpura
por: Yavaşoğlu, İrfan
Publicado: (2020)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bj5fubhkkam4prhcoepj51jmfg